Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new antibody help when thyroid eye disease comes back?

NCT ID NCT07832136

NEW Disease control Sponsor: Viridian Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing veligrotug, an intravenous antibody, in adults with moderate to severe thyroid eye disease that returned after they responded to teprotumumab. The trial enrolls about 30 participants who completed a full course of teprotumumab at least nine months earlier and then had a recurrence. Everyone receives veligrotug, and the main goal is to track side effects and see how well the drug controls the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
veligrotug, an experimental antibody given as an intravenous infusion
What this could lead to
If it works, veligrotug could offer a repeat treatment option for people whose thyroid eye disease returns after teprotumumab.
What could go wrong
This is a small, single-arm phase 4 trial with no comparison group, so results may not show whether veligrotug truly helps. Infusions can cause reactions, and the drug's safety profile is still being characterized.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Must have a diagnosis of TED with associated signs and symptoms. * Must have completed an initial full course of treatment (8 infusions over approximately 21 weeks) with teprotumumab ≥9 months prior to screening. * Must have a documented clinical response to teprotumumab. * Must have evidence of recurrence following the completion of prior teprotumumab treatment course, as measured by exophthalmometer in the study eye. * Must have a Clinical Activity Score (CAS) ≥3 in the study eye. * Must not require immediate orbital surgery in the study eye during the anticipated duration of the trial. * Must agree to use highly effective contraception as specified in the protocol. * Female TED participants must have a negative serum pregnancy test at screening. Key Exclusion Criteria: * Must not have sight-threatening TED (eg, dysthyroid optic neuropathy). * Must not have received IGF-1R inhibitor therapy within 9 months prior to screening or received any IGF-1R inhibitor other than teprotumumab at any time. * Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to the first dose. * Must not have received other immunosuppressive drugs for any condition, including TED, within 12 weeks prior to the first dose or any other therapy for TED (except for artificial tears) within 8 weeks prior to the first dose. * Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose. * Must not have previous orbital irradiation or decompression surgery for TED to the study eye's orbit. * Must not have a pre-existing ophthalmic condition in the study eye which, in the study doctor's opinion, would interfere with interpretation of trial results. * Must not have abnormal hearing test before first dose or any history of hearing impairment. Must not also have any history of ear conditions considered significant by the study doctor. * Must not have a history of inflammatory bowel disease. * Female participants must not be pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid eye disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid eye disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor College of Medicine Alkek Eye Center

    Houston, Texas, 77030, United States

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan, 48152, United States

  • Neuro-Eye Clinical Trials

    Houston, Texas, 34239, United States

  • Office of Dr. Amy Patel Jain, MD

    Newport Beach, California, 92660, United States

  • Ophthalmic Consultants of Boston

    East Weymouth, Massachusetts, 02189, United States

  • Sarasota Retina Institute

    Sarasota, Florida, 34239, United States

  • The Center for Eye and Facial Plastic Surgery

    Somerset, New Jersey, 08873, United States

  • University Health

    Kansas City, Missouri, 64108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.